Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-43017
Stupp, R; Weller, M (2010). 2010: neuro-oncology is moving! Current Opinion in Neurology, 23(6):553-555.
- Registered users only
View at publisher
The first randomized phase III trial in patients with primary central nervous system lymphoma was reported for the first time at the 2010 annual meeting of the American Society of Clinical Oncology, and concluded that the omission of whole brain radiotherapy from first-line treatment does not compromise survival. Two randomized trials investigated tailored treatment strategies for elderly patients with glioma and reached opposite conclusions. Novel treatment approaches in recurrent glioblastoma with alternating tumour treatment fields (NovoTTF), or antiangiogenic agents (cilengitide and bevacizumab) have been reported and updated. The role of vascular endothelial growth factor-inhibiting strategies in the management of recurrent glioma remains unclear and controversial.
17 downloads since deposited on 26 Jan 2011
3 downloads since 12 months
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology|
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||26 Jan 2011 19:31|
|Last Modified:||27 Nov 2013 22:37|
|Publisher:||Lippincott Wiliams & Wilkins|
|Additional Information:||This a non-final version of an article published in final form in Current Opinion in Neurology, 23(6):553-555. DOI: 10.1097/WCO.0b013e3283407eed|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page